SCHEMBL1480652

SCHEMBL1480652

C=Cc1ccc(OC)c(OC)c1OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 4/20 0.53
CYP1B1 Q16678 4/20 0.53
MAPT P10636 4/20 0.51
ALDH1A1 P00352 2/20 0.51
KMT2A Q03164 2/20 0.51
CYP19A1 P11511 1/20 0.51
POLB P06746 1/20 0.51
ABCG2 Q9UNQ0 1/20 0.50
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
CYP1A2 P05177 3/20 0.47
KDM4E B2RXH2 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
NFE2L2 Q16236 1/20 0.46
SIRT1 Q96EB6 1/20 0.45
CYP2D6 P10635 1/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29110557 0.89 CYP1A1 (0.38) CYP1A1CYP1B1MAPTALDH1A1KMT2A
SCHEMBL19416799 0.83 CYP1A1 (0.42) CYP1A1CYP1B1MAPTALDH1A1KMT2A
SCHEMBL31403390 0.83 CYP1A1 (0.47) CYP1A1CYP1B1MAPTALDH1A1KMT2A
SCHEMBL6216044 0.83 ALDH1A1 (0.40) CYP1A1CYP1B1MAPTALDH1A1KMT2A
SCHEMBL7927094 0.83 CYP1A1 (0.39) CYP1A1CYP1B1MAPTALDH1A1KMT2A
SCHEMBL11270049 0.83 CYP1A1 (0.53) CYP1A1CYP1B1MAPTALDH1A1KMT2A
SCHEMBL8910888 0.82 CYP1A1 (0.56) CYP1A1CYP1B1MAPTALDH1A1KMT2A
SCHEMBL1030266 0.82 POLB (0.47) CYP1A1CYP1B1MAPTALDH1A1KMT2A
SCHEMBL57085 0.81 NFE2L2 (0.58) CYP1A1CYP1B1MAPTCYP19A1CYP1A2
SCHEMBL8502492 0.80 CYP1A1 (0.56) CYP1A1CYP1B1MAPTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-210942955-U Packaging bag of moisture curing polymer 江苏科幸新材料有限公司 2020-07-07 CN claimed
CN-104761537-B Preparation method of beta-chloro-1,3-dithiane derivative 兰州大学 2017-02-15 CN claimed
CN-104761537-A Preparation method of beta-chloro-1,3-dithiane derivative UNIV LANZHOU 2015-07-08 CN claimed
JP-2006518738-A 2006-08-17 JP claimed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP claimed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO claimed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US claimed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO claimed
EP-0787750-B1 Poly(alkylethylene) structural isomers BOREALIS GMBH (AT) 2003-05-14 EP claimed
US-12030974-B2 Composition for forming block copolymer layer for formation of microphase-separated pattern NISSAN CHEMICAL CORPORATION (JP) 2024-07-09 US disclosed
US-12030974-B2 Composition for forming block copolymer layer for formation of microphase-separated pattern NISSAN CHEMICAL CORPORATION (JP) 2024-07-09 US disclosed
US-20230399300-A1 METHODS OF SYNTHESIZING 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL] PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE IMBRIA PHARMACEUTICALS, INC. 2023-12-14 US disclosed
US-11780811-B2 Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate IMBRIA PHARMACEUTICALS, INC. (US) 2023-10-10 US disclosed
US-20230280654-A1 UPPER FILM-FORMING COMPOSITION AND METHOD FOR PRODUCING PHASE-SEPARATED PATTERN NISSAN CHEMICAL CORPORATION (JP) 2023-09-07 US disclosed
EP-0787750-A2 Poly(alkylethylene) structural isomers PCD-Polymere Gesellschaft m.b.H. (AT) 1997-08-06 EP disclosed
EP-0574510-A4 NEOLIGNAN DERIVATIVES AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS AND 5-LIPOXYGENASE INHIBITORS INNOVATIVE TECH CENTER (US) 1994-07-06 EP disclosed
US-5326489-A Sulfonated polymer NIPPON SHOKUBAI CO., LTD. (JP) 1994-07-05 US disclosed
EP-0523300-B1 Electrorheological fluids NIPPON CATALYTIC CHEM IND (JP) 1994-01-19 EP disclosed
EP-0574510-A1 NEOLIGNAN DERIVATIVES AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS AND 5-LIPOXYGENASE INHIBITORS CENTER FOR INNOVATIVE TECHNOLOGY (US) 1993-12-22 EP disclosed
EP-0523300-A1 Electrorheological fluids NIPPON SHOKUBAI KAGAKU KOGYO CO. LTD. (JP) 1993-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ CYP1A1 697/4885CYP1B1 345/4885MAPT 3558/4885
US-11780811-B2 Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate TET3, TET2, TET1 CYP1A1 490/4885CYP1B1 2015/4885MAPT 4224/4885
US-20230399300-A1 METHODS OF SYNTHESIZING 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL] PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE TET3, TET2, TET1 CYP1A1 490/4885CYP1B1 2015/4885MAPT 4224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.